Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: a Cancer J Clin. 2022;72:7–33.

Google Scholar 

Bast RC Jr, Lu Z, Han CY, Lu KH, Anderson KS, Drescher CW, et al. Biomarkers and strategies for early detection of ovarian cancer. Cancer Epidemiol, Biomark Prev. 2020;29:2504–12.

CAS  Google Scholar 

Ma Z, Li Q, Liu P, Dong W, Zuo Y. METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP. Cell Biol Int. 2020;44:2524–31.

CAS  PubMed  Google Scholar 

Zhao L, Kong X, Zhong W, Wang Y, Li P. FTO accelerates ovarian cancer cell growth by promoting proliferation, inhibiting apoptosis, and activating autophagy. Pathology, Res Pract. 2020;216:153042.

CAS  Google Scholar 

Wu Q, Li G, Gong L, Cai J, Chen L, Xu X, et al. Identification of miR-30c-5p as a tumor suppressor by targeting the m(6) A reader HNRNPA2B1 in ovarian cancer. Cancer Med. 2022;12:5055–70.

Huang H, Wang Y, Kandpal M, Zhao G, Cardenas H, Ji Y, et al. FTO-Dependent N (6)-Methyladenosine modifications inhibit ovarian cancer stem cell self-renewal by blocking cAMP signaling. Cancer Res. 2020;80:3200–14.

CAS  PubMed  PubMed Central  Google Scholar 

Liu T, Wei Q, Jin J, Luo Q, Liu Y, Yang Y, et al. The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic Acids Res. 2020;48:3816–31.

CAS  PubMed  PubMed Central  Google Scholar 

Ou X, Tan Y, Xie J, Yuan J, Deng X, Shao R, et al. Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer. Drug Resist Updates. 2024;73:101063.

CAS  Google Scholar 

Huang C, Xu R, Zhu X, Jiang H. m6A-modified circABCC4 promotes stemness and metastasis of prostate cancer by recruiting IGF2BP2 to increase stability of CCAR1. Cancer Gene Ther. 2023;30:1426–40.

CAS  PubMed  Google Scholar 

Xiao T, Wang P, Wu M, Cheng C, Yang Y, Bian Q, et al. METTL3-regulated m6A modification of lncRNA E230001N04Rik is involved in myofibroblast differentiation in arsenic-induced pulmonary fibrosis through promoting senescence of lung epithelial cells. J Hazard Mater. 2024;480:136094.

CAS  PubMed  Google Scholar 

Jiang Y, Wan Y, Gong M, Zhou S, Qiu J, Cheng W. RNA demethylase ALKBH5 promotes ovarian carcinogenesis in a simulated tumour microenvironment through stimulating NF-kappaB pathway. J Cell Mol Med. 2020;24:6137–48.

CAS  PubMed  PubMed Central  Google Scholar 

Tang C, Klukovich R, Peng H, Wang Z, Yu T, Zhang Y, et al. ALKBH5-dependent m6A demethylation controls splicing and stability of long 3’-UTR mRNAs in male germ cells. Proc Natl Acad Sci USA. 2018;115:E325–33.

CAS  PubMed  Google Scholar 

Peng ZY, Xiao PJ, Qi Y, Zhang W, Chen XH, Xu P. NSSR1 is regulated by testosterone in the mouse uterus and extensively expressed in endometrial carcinoma. Tumour Biol. 2011;32:359–66.

CAS  PubMed  Google Scholar 

Li K, Chen J, Lou X, Li Y, Qian B, Xu D, et al. HNRNPA2B1 affects the prognosis of esophageal cancer by regulating the miR-17-92 Cluster. Front Cell Dev Biol. 2021;9:658642.

PubMed  PubMed Central  Google Scholar 

Győrffy B. Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer. GeroScience. 2023;45:1889–98.

PubMed  PubMed Central  Google Scholar 

Meng Z, Yuan Q, Zhao J, Wang B, Li S, Offringa R, et al. The m(6)A-Related mRNA signature predicts the prognosis of pancreatic cancer patients. Mol Ther Oncolytics. 2020;17:460–70.

CAS  PubMed  PubMed Central  Google Scholar 

Bai X, Ni J, Beretov J, Wang S, Dong X, Graham P, et al. THOC2 and THOC5 regulate stemness and radioresistance in triple-negative breast cancer. Adv Sci. 2021;8:e2102658.

Google Scholar 

Zhou X, Li X, Cheng Y, Wu W, Xie Z, Xi Q, et al. BCLAF1 and its splicing regulator SRSF10 regulate the tumorigenic potential of colon cancer cells. Nat Commun. 2014;5:4581.

CAS  PubMed  Google Scholar 

Hua W, Zhao Y, Jin X, Yu D, He J, Xie D, et al. METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition. Gynecol Oncol. 2018;151:356–65.

CAS  PubMed  Google Scholar 

Zhang S, Zhao BS, Zhou A, Lin K, Zheng S, Lu Z, et al. m(6)A Demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program. Cancer Cell. 2017;31:591–606.e596.

CAS  PubMed  PubMed Central  Google Scholar 

He Y, Hu H, Wang Y, Yuan H, Lu Z, Wu P, et al. ALKBH5 inhibits pancreatic cancer motility by decreasing long non-coding RNA KCNK15-AS1 Methylation. Cellular Physiol Biochem. 2018;48:838–46.

CAS  Google Scholar 

Nie S, Zhang L, Liu J, Wan Y, Jiang Y, Yang J, et al. ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer. J Exp Clin cancer Res. 2021;40:284.

CAS  PubMed  PubMed Central  Google Scholar 

Zhu H, Gan X, Jiang X, Diao S, Wu H, Hu J. ALKBH5 inhibited autophagy of epithelial ovarian cancer through miR-7 and BCL-2. J Exp Clin Cancer Res. 2019;38:163.

PubMed  PubMed Central  Google Scholar 

Roundtree IA, He C. Nuclear m(6)A reader YTHDC1 regulates mRNA splicing. Trends Genet. 2016;32:320–1.

CAS  PubMed  Google Scholar 

Ladomery M. Aberrant alternative splicing is another hallmark of cancer. Int J Cell Biol. 2013;2013:463786.

PubMed  PubMed Central  Google Scholar 

Singh S, Narayanan SP, Biswas K, Gupta A, Ahuja N, Yadav S, et al. Intragenic DNA methylation and BORIS-mediated cancer-specific splicing contribute to the Warburg effect. Proc Natl Acad Sci USA. 2017;114:11440–5.

CAS  PubMed  PubMed Central  Google Scholar 

Yadav S, Pant D, Samaiya A, Kalra N, Gupta S, Shukla S. ERK1/2-EGR1-SRSF10 axis mediated alternative splicing plays a critical role in head and neck cancer. Front Cell Dev Biol. 2021;9:713661.

PubMed  PubMed Central  Google Scholar 

Wang S, Wang Z, Li J, Qin J, Song J, Li Y, et al. Splicing factor USP39 promotes ovarian cancer malignancy through maintaining efficient splicing of oncogenic HMGA2. Cell Death Dis. 2021;12:294.

PubMed  PubMed Central  Google Scholar 

Wang Z, Wang S, Qin J, Zhang X, Lu G, Liu H, et al. Splicing factor BUD31 promotes ovarian cancer progression through sustaining the expression of anti-apoptotic BCL2L12. Nat. Commun. 2022;13:6246.

CAS  PubMed  PubMed Central  Google Scholar 

Diao Y, Li Y, Wang Z, Wang S, Li P, Kong B. SF3B4 promotes ovarian cancer progression by regulating alternative splicing of RAD52. Cell Death Dis. 2022;13:179.

CAS  PubMed  PubMed Central  Google Scholar 

Shin C, Feng Y, Manley JL. Dephosphorylated SRp38 acts as a splicing repressor in response to heat shock. Nature. 2004;427:553–8.

CAS  PubMed  Google Scholar 

Shin C, Manley JL. The SR protein SRp38 represses splicing in M phase cells. Cell. 2002;111:407–17.

CAS  PubMed  Google Scholar 

Feng Y, Chen M, Manley JL. Phosphorylation switches the general splicing repressor SRp38 to a sequence-specific activator. Nat Struct Mol Biol. 2008;15:1040–8.

CAS  PubMed  PubMed Central  Google Scholar 

Liu F, Dai M, Xu Q, Zhu X, Zhou Y, Jiang S, et al. SRSF10-mediated IL1RAP alternative splicing regulates cervical cancer oncogenesis via mIL1RAP-NF-kappaB-CD47 axis. Oncogene. 2018;37:2394–409.

CAS  PubMed  PubMed Central  Google Scholar